Aktienanalyse zu Dermata Therapeutics Inc (DRMA)DRMADermata Therapeutics Inc

Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Dermata Therapeutics is not a good buy right now due to a current price of $1.34, which is significantly below the analyst's price target of $4. Additionally, the RSI is at 38.725, indicating potential oversold conditions but also a lack of upward momentum. The company reported a net loss of $2.97 million in Q2 2026, which is a widening loss from the previous year, highlighting ongoing financial struggles.